vp 16-213 ( etoposide , abbr . to vp ) , an oncostatic drug , was administered intravenously to female crj : cd ( sprague-dawley ) rats from day 17 of gestation through postpartum day 20 at dose levels of 0.05 , 0.2 and 0.8 mg/kg/day .
C0015133
etoposide
C0032961
gestation